Genomate Health

04/07/2026

This World Health Day, we’re standing with science 💚

Better outcomes start with better understanding, and every patient deserves care shaped by evidence, collaboration, and progress.

World Health Organization (WHO)

04/03/2026

Precision oncology holds enormous promise, but for many patients, the reality is still fragmented, complex, and difficult to navigate. Too often, treatment decisions are based on partial insights, leaving both patients and clinicians without the full picture of the disease.

This La Presse article touches on a critical shift: moving beyond isolated mutations toward a more complete, integrated understanding of cancer. At Genomate Health, we focus on exactly this challenge: helping make sense of the full molecular complexity of each patient’s cancer so that decisions are clearer, more confident, and truly personalized.

Merci de nous avoir cités et d'avoir mis en lumière ces enjeux cruciaux pour les patients, Mathieu Perreault !

Read the full article here:

Parmi les dizaines de milliers de médicaments dont le brevet est expiré, certains ont des effets anticancer. Ils sont toutefois souvent ignorés dans les plans de traitement, faute d’être assez rentables. Une biologiste américaine veut changer la donne grâce à l’IA et faire en sorte que sa...

03/31/2026

We’re proud to contribute to , an Innovative Health Initiative (IHI) project bringing together more than 60 partners across Europe and beyond.

Over the next five years, COMPASS will work to improve outcomes for cancer patients by enabling earlier risk prediction, more coordinated care, and truly personalized treatment pathways.

At Genomate Health, we’re contributing our computational reasoning approach to help translate complex molecular data into clinically actionable insights, supporting better decisions across the patient journey.

Together, we’re helping bridge oncology and cardiovascular care to improve both cancer outcomes and long-term health. Learn more: https://www.genomate.health/news-article/genomate-health-contributes-to-eu-funded-compass-project

03/30/2026

Colorectal cancer is changing, and we need to pay attention.

Once considered a disease of older adults, it is now rising in younger populations, increasing by ~3% each year in people under 50. Today, nearly 1 in 5 cases is diagnosed before age 55.

The bigger problem? Many younger patients are diagnosed too late, because they don’t expect cancer, and neither does the system.

What to watch for:
• Persistent changes in bowel habits
• Blood in stool
• Unexplained weight loss or fatigue
• Ongoing abdominal discomfort
If something feels off, don’t ignore it. Push for answers.

At Genomate Health, we help patients and doctors get clearer answers about what’s driving each cancer, so they can make the right decisions, faster. Because when diagnosis comes late, every decision matters.

It’s time our understanding and our actions catch up with the reality of this disease.

03/24/2026

You don’t just want more information.
You want to feel sure.

After a cancer diagnosis, it’s normal to question everything: Is this the right treatment? Is there something we’re missing?

At Genomate Health, we’re here to help you find clarity.
Our Second Opinion Service looks at your cancer in its full complexity, combining advanced computational reasoning with expert clinical insight, so you can better understand your options and move forward with confidence.

Not just more data. A complete picture.
Because better insight leads to better decisions.

Learn more: https://www.genomate.health/services/second-opinion

03/18/2026

We're happy to announce that Genomate Health will present three abstracts at the American Association for Cancer Research (AACR Journals) Annual Meeting, taking place April 17–22, 2026 in San Diego.

The accepted work spans preclinical, real-world, and clinical decision-making settings, demonstrating the applicability of computational reasoning across the full spectrum of oncology research and care. The presentations include:

👉 Prediction of treatment efficacy in GDSC cell line data, validating computational reasoning in preclinical models: https://www.genomate.health/publication/genomate-treatment-efficacy-predictivity-in-gdsc-cell-line-data

👉 Prediction of treatment outcomes in the GENIE BPC NSCLC cohort, using large-scale real-world clinico-genomic data: https://genomate.health/publication/genomate-treatment-efficacy-predictivity-in-genie-bpc-nsclc-cohort

👉 A late-breaking abstract on clinical efficacy, evaluating personalized treatment planning in a real-world, multidisciplinary tumor board setting: https://www.abstractsonline.com/pp8/ #!/21436/presentation/11352

Together, these studies reinforce a consistent finding: while molecular data continues to expand, the key challenge in precision oncology is no longer data generation, but how to translate complexity into actionable treatment decisions at scale.

Our work shows that computational reasoning can bridge that gap, enabling:
✔️ Better prediction of treatment efficacy
✔️ More consistent decision support across patients
✔️ Scalable personalization in real-world settings

If this is a problem you’re looking to solve, we should talk. Come find us at , we’d love to continue the conversation.

03/13/2026

Cancer has a way of taking over everything: your time, your attention, your conversations, your plans. But behind every diagnosis is still your life, your family, and the moments that matter most.

The Genomate Second Opinion Service was created to help you make treatment decisions with greater clarity, so cancer doesn’t have to define every choice you make.

By combining molecular expertise, advanced computational analysis, and the clinical judgment of a licensed oncologist, we look deeper into the biology of your cancer and review the treatment options that may make sense for your specific case. You’ll meet with an oncologist who walks you through the analysis and provides a clear written report you can revisit or share with your care team.

Because the goal isn’t just another opinion.

It’s the reassurance that your decision was made with the fullest understanding possible, so you can spend less time worrying and more time focusing on the people and moments that truly matter.

Learn more:
https://www.genomate.health/services/second-opinion

03/11/2026

Most cancer treatment decisions are made under enormous pressure.

Patients and families are asked to choose a path forward while facing uncertainty, complex data, and limited time. And often while wondering: “𝐀𝐦 𝐈 𝐠𝐞𝐭𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭?”

At Genomate Health, we believe you deserve the chance to understand your cancer as deeply as possible before making those decisions. That’s why we’re launching the Genomate Second Opinion Service.

This service brings together three layers of expertise:
1️⃣ Molecular genetics experts who carefully review your existing NGS results
2️⃣ Genomate’s computational reasoning platform, which analyzes cancer as a connected biological system
3️⃣ A licensed oncologist, who reviews the full analysis and delivers a personalized medical second opinion

Here’s what you receive:
✔️ A deep analysis of your cancer, not just individual mutations, but how the tumor works as a system
✔️ Independent review by molecular experts and a licensed oncologist
✔️ A telehealth consultation where the oncologist walks through what was considered and why
✔️ A clear written report you can share with your care team to support next steps. It explains the treatment options evaluated, the clinical reasoning behind them, and the supporting scientific evidence.

Because when facing cancer, you deserve to move forward knowing every option has been carefully considered.

Learn more about the Genomate Second Opinion Service:
https://www.genomate.health/services/second-opinion

03/09/2026

Every cancer diagnosis begins with uncertainty.
For many patients with kidney cancer, the questions come quickly:
What does this mean for me?
Which treatment is the right one?
Do we truly understand my cancer?

The reality is that no two kidney cancers are the same. Behind the diagnosis lies a complex molecular story that can shape how a tumor behaves and how it may respond to treatment.

On World Kidney Day, and during Kidney Cancer Awareness Month, we are reminded that better decisions in cancer care start with better understanding.

At Genomate Health, we help uncover the full molecular complexity of each patient’s cancer using computational reasoning, turning vast molecular data into insights that can support more informed treatment choices.

Because for every patient facing cancer, clarity matters.
And every patient deserves a treatment strategy built on the complete picture of their disease.

03/04/2026

Our team at Genomate Health works every day to support better cancer treatment decisions through computational reasoning.

But one of the most powerful tools against cancer isn’t treatment, it’s prevention.

Today, on HPV Awareness Day, we’re reminded that many cancers can be prevented through vaccination, screening, and awareness. HPV is responsible for nearly all cervical cancers and a growing number of other cancers. Yet millions of people around the world still lack access to the information, prevention, and care that could significantly reduce their risk.

As a team working in precision oncology, we see firsthand how important earlier action can be. Preventing cancer, or detecting it early, changes everything for patients.

Today we stand with clinicians, researchers, and public health advocates working to reduce HPV-related cancers and protect future generations.

Because the best cancer to treat is the one that never develops.

02/28/2026

Rare diseases challenge medicine in a different way.

Fewer cases mean fewer studies. Less consensus. More uncertainty. And for patients, that uncertainty can delay answers and limit options.

At Genomate Health, this is exactly where structured, evidence-based reasoning matters most. Our computational reasoning approach does not rely on frequency. It evaluates the full molecular profile of a tumor, aggregates available evidence, and prioritizes therapies based on biological relevance. That matters especially in rare cancers, where clinical experience may be limited and every decision carries weight.

On , we reaffirm our commitment to making precision oncology work not only for the many, but also for the few.

Because rare diseases are not rare for the people living with them.

02/16/2026

When a child is diagnosed with cancer, everything changes. For the family. For the care team. And for those working behind the scenes to help find the best possible path forward.

At Genomate Health, we think about the young patients whose molecular profiles we review. A name. An age. A life just beginning. A child whose doctors are searching for clarity in the face of complexity.

That responsibility shapes how we work. It drives our rigor. It demands precision. It reminds us that behind every dataset is a future that deserves protecting.

Today, we stand with children and families navigating the unimaginable. And we recommit to doing our part, so that every child facing cancer has the strongest, most informed care possible behind them.